{"nctId":"NCT00368745","briefTitle":"Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.","startDateStruct":{"date":"2006-09"},"conditions":["Generalized Anxiety Disorder"],"count":108,"armGroups":[{"label":"Pregabalin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pregabalin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pregabalin","otherNames":["Lyrica"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide written informed consent\n* 18-65 years old\n* male and female\n* A primary lifetime diagnosis of DSM-IV-TR (2000) GAD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition)\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* History of non-response to alprazolam, other benzodiazepines, gabapentin or pregabalin given for the treatment of anxiety as indicated by a (screening or baseline) Hamilton Anxiety Scale (HAM-A) score \\> 18","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects at Endpoint (Post Alprazolam Free Week 6 or Last Observation Carried Forward [LOCF] Post Alprazolam Free Week 1) Who Are Benzodiazepine Free","description":"Number of subjects benzodiazepine free: \\< 2 doses rescue medication; negative urine benzodiazepine psychoactive toxicology assay (each visit Alprazolam Free phase); negative serum benzodiazepine alcohol assay (endpoint or LOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Hamilton Anxiety Scale (HAM-A) Scores","description":"HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); lower score indicates less affected. Change from baseline: mean at observation minus mean at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"0.66"},{"groupId":"OG001","value":"0.67","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.72","spread":"0.98"},{"groupId":"OG001","value":"2.17","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.59","spread":"0.99"},{"groupId":"OG001","value":"-0.21","spread":"1.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.47","spread":"1.11"},{"groupId":"OG001","value":"1.91","spread":"1.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.36","spread":"2.19"},{"groupId":"OG001","value":"2.86","spread":"2.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","spread":"1.40"},{"groupId":"OG001","value":"2.41","spread":"2.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.90"},{"groupId":"OG001","value":"2.40","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.15","spread":"0.91"},{"groupId":"OG001","value":"-1.14","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.46","spread":"0.92"},{"groupId":"OG001","value":"-2.47","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.58","spread":"0.84"},{"groupId":"OG001","value":"-3.58","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.85","spread":"0.87"},{"groupId":"OG001","value":"-3.34","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.62","spread":"0.84"},{"groupId":"OG001","value":"-4.77","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.01","spread":"1.13"},{"groupId":"OG001","value":"2.77","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With > = 6 Point Increase in Physician's Withdrawal Checklist (PWC) Scores","description":"PWC: 20 item physician rated interview (0 = not present; 3 = severe; score range: 0 to 60) measuring: signs of anxiolytic drug withdrawal and gastrointestinal (GI), mood, sleep, motor, somatic, perception and cognition symptoms. Data not analyzed: PWC not measured at baseline.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Subjects With > = 5 New PWC Symptoms","description":"PWC: 20 item physician rated interview (0 = not present; 3 = severe; score range: 0 to 60) measuring: signs of anxiolytic drug withdrawal and gastrointestinal (GI), mood, sleep, motor, somatic, perception and cognition symptoms. Data not analyzed: PWC not measured at baseline.","paramType":null,"dispersionType":null,"classes":[]},{"type":"POST_HOC","title":"Mean Scores Physician's Withdrawal Checklist (PWC)","description":"Mean scores at each visit for PWC: 20-item physician-rated interview measures presence of anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception, and cognition); range 0 (not present) to 3 (severe). Total score: 0 to 60; higher score = more affected. Mean scores entered as post-hoc analysis as Mean change from baseline in PWS scores not analyzed: PWS not measured at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.32","spread":"1.40"},{"groupId":"OG001","value":"8.50","spread":"1.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.37","spread":"1.18"},{"groupId":"OG001","value":"10.00","spread":"1.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.56","spread":"1.40"},{"groupId":"OG001","value":"9.41","spread":"1.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.63","spread":"0.89"},{"groupId":"OG001","value":"9.04","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.30","spread":"1.52"},{"groupId":"OG001","value":"9.58","spread":"2.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.82","spread":"1.39"},{"groupId":"OG001","value":"12.55","spread":"2.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.78","spread":"1.15"},{"groupId":"OG001","value":"10.70","spread":"1.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"0.93"},{"groupId":"OG001","value":"6.43","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.86","spread":"0.85"},{"groupId":"OG001","value":"7.16","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.43","spread":"0.89"},{"groupId":"OG001","value":"6.99","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.87","spread":"0.76"},{"groupId":"OG001","value":"8.25","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"0.94"},{"groupId":"OG001","value":"5.51","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.48","spread":"1.23"},{"groupId":"OG001","value":"10.28","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Physician's Withdrawal Checklist (PWC) Scores","description":"PWC: 20 item physician rated interview (0 = not present; 3 = severe; score range: 0 to 60) measuring: signs of anxiolytic drug withdrawal and gastrointestinal (GI), mood, sleep, motor, somatic, perception and cognition symptoms. Change from baseline not analyzed as PWC was not measured at baseline. Mean PWS scores presented in Post-hoc outcome measure Mean PWS scores.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Mean Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Scores.","description":"CGI-S: 7-point scale to assess global change in subject condition compared to baseline; range 1 (no evidence of illness) to 7 (among the most severely ill); higher score = more affected. Change from baseline: mean at observation minus mean at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"0.13"},{"groupId":"OG001","value":"0.22","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.17"},{"groupId":"OG001","value":"0.41","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.20"},{"groupId":"OG001","value":"-0.10","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"0.21"},{"groupId":"OG001","value":"-0.04","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"0.27"},{"groupId":"OG001","value":"-0.05","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"0.32"},{"groupId":"OG001","value":"0.08","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"0.17"},{"groupId":"OG001","value":"0.23","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"0.20"},{"groupId":"OG001","value":"-0.48","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"0.22"},{"groupId":"OG001","value":"-0.32","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":"0.18"},{"groupId":"OG001","value":"-0.84","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"0.19"},{"groupId":"OG001","value":"-0.75","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":"0.20"},{"groupId":"OG001","value":"-1.02","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.21"},{"groupId":"OG001","value":"0.31","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Mean Scores for Clinical Global Impression-Improvement (CGI-I) Scale","description":"CGI-I: 7-point scale to assess global change in subject condition compared to baseline; range 1 (very much improved) to 7 (very much worse); higher score = more affected.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.52","spread":"0.20"},{"groupId":"OG001","value":"3.90","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.17","spread":"0.27"},{"groupId":"OG001","value":"3.98","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"0.31"},{"groupId":"OG001","value":"3.47","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.09","spread":"0.35"},{"groupId":"OG001","value":"3.01","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.63","spread":"0.30"},{"groupId":"OG001","value":"3.44","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":"0.31"},{"groupId":"OG001","value":"3.86","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"0.28"},{"groupId":"OG001","value":"3.90","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":"0.28"},{"groupId":"OG001","value":"3.27","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"0.28"},{"groupId":"OG001","value":"2.93","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"0.29"},{"groupId":"OG001","value":"2.46","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"0.32"},{"groupId":"OG001","value":"2.77","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"0.28"},{"groupId":"OG001","value":"2.18","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"0.30"},{"groupId":"OG001","value":"3.52","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Mean Scores for Patient Global Impression-Improvement (PGI-I)","description":"PGI-I: subject rated 7-point scale measures change in overall status; range 1 (very much improved) to 7 (very much worse).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","spread":"0.23"},{"groupId":"OG001","value":"3.82","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"0.32"},{"groupId":"OG001","value":"4.03","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"0.28"},{"groupId":"OG001","value":"3.31","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.12","spread":"0.34"},{"groupId":"OG001","value":"2.98","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"0.37"},{"groupId":"OG001","value":"3.75","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"0.42"},{"groupId":"OG001","value":"3.38","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.95","spread":"0.26"},{"groupId":"OG001","value":"3.45","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"0.27"},{"groupId":"OG001","value":"2.94","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"0.28"},{"groupId":"OG001","value":"2.92","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":"0.29"},{"groupId":"OG001","value":"2.73","spread":"0.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","spread":"0.31"},{"groupId":"OG001","value":"2.70","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"0.27"},{"groupId":"OG001","value":"2.48","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","spread":"0.32"},{"groupId":"OG001","value":"3.74","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Digit Symbol Substitution Test (DSST) Scores","description":"DSST: subject-rated; evaluates aspects of cognition (includes attending to directions, processing speed, sustained attention, visual-motor integration, learning and psychomotor speed). Subject matches symbol (1 to 9) with corresponding number key (1 to 9); number of correct symbol-number pairs completed by subject over a 90-second test period determines DSST score. Change: mean at observation minus mean at baseline. Data summarized as change from baseline to endpoint.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.10","spread":"2.64"},{"groupId":"OG001","value":"13.47","spread":"2.95"}]}]}]},{"type":"SECONDARY","title":"Time to Discontinuation","description":"The 25th percentile estimate of time until discontinuation is based on Kaplan-Meier estimates. Event day is the study day when the subject discontinued from study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Use of Rescue Medication","description":"The 25th percentile estimate of time until first use of rescue medication is based on Kaplan-Meier estimates. Event day is the study day when the subject first used rescue medication. Rescue medication: packet with 2 doses alprazolam to take only in the event subject experiences severe symptoms of benzodiazepine withdrawal or rebound anxiety.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects in Relapse Free State at 6-week Benzodiazepine-free Endpoint (Alprazolam Free Week 6)","description":"Number of subjects benzodiazepine free: \\< 2 doses rescue medication; negative urine toxicology assay (each visit Alprazolam Free phase), negative urine alcohol assay (Alprazolam Free Week 6 = endpoint or LOCF). Relapse: \\> = 2 intakes rescue medication, positive urine and /or alcohol assays, unable to tolerate alprazolam taper, or discontinuation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Anxiety","Headache","Dizziness","Nausea","Insomnia"]}}}